BUY

It did miss its last quarter's earnings but the core business is still doing well. There is maybe short term volatility but have patience. Banks are held for the long term and Royal Bank is good for the long term.

WATCH

She is following it. Has a good dividend of 4.6 to 4.7. It is very volatile but is one of the best positioned with a strong balance sheet. She sees upside and free cash flow of 9%. It is one of the fastest growing in the offshore basin. There is an oil overhang due to softer prices but you could set up for a compelling entry price point.

BUY

There is a lot of noise around it but it is one of the largest companies in the world, although not one of the leaders. It is one of the worst in the AI space. The fundamentals should do well but it might take a while for it to reach its 15% upside. She gives it a 3 out of 10 for valuation.  It is a money making machine with most of the bad news priced in. She is starting to see some sells. If owned you could trim your position.

TOP PICK

It is in the industrial space which she likes. Has a $2 billion backlog. It is now re-focusing on high value sectors. She sees 18% earnings per share growth and 20% upside overall. It has strong momentum and she rates it an 8 out of 10.             Buy 6  Hold 2  Sell 1

(Analysts’ price target is $51.47)
TOP PICK

She likes the royalty models which don't have the risks of operating mines. Its copper, potash, etc. covers the structural growth sectors. She sees 24% upside from here. It has steady cash flow, low net debt and a weaker U..S. dollar is good for it. It scores 9 out of 10 for fundamentals.
Buy 5  Hold 1  Sell 0

(Analysts’ price target is $33.67)
TOP PICK

A leader in software it is also a pioneer in staff models. It is evolving into an operating system for more modern enterprises and AI. It has a good valuation at 22 X earnings and she sees 36% upside. Through its share buybacks and dividends it is providing good shareholder returns. Although it is down 23% year-to-date she gives it a 9 out of 10.         Buy 51  Hold 10  Sell 2

(Analysts’ price target is $353.69)
COMMENT

You can't bet against their eco-system and their ability to buy back shares, but now there are many tech competitors to buy.

BUY

He owns it for their data centre build. 

SELL

Is at risk of single-digit revenue growth in 2025, and the last time that happened was 2014. He sold. 

BUY

It's near an all-time high, just made a week ago. Israel is the second-leading exporter of tech, alongside the U.S. He bought on the recent geopolitical pullback. This holds 30% tech, 30% financials.

BUY

The PE is rich in the mid-50s, but has 20% revenue growth, and they have a revolutionary medical device, an insulin patch. Have a new CEO. 

DON'T BUY

The momentum has broken badly and has a high PE. But he entered this on a rebound that has momentum. Despite an upgrade today, he doesn't see a green light ahead.

BUY

A rich valuation like many medical device companies, but he's sticking with it. Earnings growth is there.

BUY

She is overweight and bought more. Retail stores can't find workers and suffer threat. So, Amazon becomes the only alternative in retail. Their retail business is getting another lift higher now.

BUY

Still owns it. The market liked what Meta said on the ad front, where clients can create their own ads with tools that Meta supplies--a game changer.